Ichor meets $18,000 crowd-funding goal in just 7 days

Syracuse, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced today that its first crowd-funding campaign has met its $18,000 goal in only 7 days. These funds will be used to study the effects of c60, a potent antioxidant, on human cancer proliferation. Longecity.org and a private donor pledged two dollars in additional contributions for every dollar raised by the campaign.

Ichor CEO Kelsey Moody stated, “We are simply blown away by such a positive reception from the Longecity community.” He further noted, “I cannot begin to convey my appreciation to Methuselah Foundation, Longecity, and all our donors for supporting us in this endeavor. We look forward to rewarding your confidence in our work.”

This crowd-funding campaign comes just a month after Ichor announced a $383,000 research contract with BioSenex, Ltd. to study the effects of select supplements on aging in mice, including c60. The Ichor Therapeutics crowd-funding campaign is still ongoing, and further contributions will be used to expand the study to include a solid tumor model. To make a tax-deductible donation, please visit this link.

About Ichor Therapeutics, Inc.: Ichor Therapeutics, Inc. (www.ichortherapeutics.com) is a privately held pre-clinical biotechnology company in Syracuse, NY. Founded in 2013 by then SUNY Upstate Medical University student Kelsey Moody, the company has raised over $1 million to support its research programs. Ichor owns and operates the online store WeCellStuff.com.